A Phase 1/2a Open Label Trial to Assess Safety and Immunogenicity of Candidate T-cell Vaccines ChAdOx1.HTI and MVA.HTI Given Sequentially to Healthy HIV-1/2 Negative Adult Volunteers in Oxford, UK
Latest Information Update: 02 Sep 2022
At a glance
- Drugs HTI immunogen (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 31 Aug 2022 Status changed from active, no longer recruiting to completed.
- 22 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Aug 2022.
- 22 Jun 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Aug 2022.